BREAKING: Supreme Court to Consider Fifth Circuit's Abortion Pill Decision
The Court granted two petitions for certiorari seeking review of a controversial lower court decision limiting federal approval of mifepristone.
The Court granted two petitions for certiorari seeking review of a controversial lower court decision limiting federal approval of mifepristone.
Your donations help us take on today's Prohibitionists.
Lots of Americans have an intolerance to FODMAPs—the sugars prevalent in garlic, onion, and many other foods.
"The FDA's regulations related to animal testing no longer fully conform with applicable law," writes the Kentucky senator.
Policies inspired by that exaggerated threat continue to undermine the harm-reducing potential of e-cigarettes.
The DAIRY PRIDE Act says it wants to protect consumers. In reality, it's trying to protect dairy farmers from economic competition.
Brazil now has one of the largest cigarette markets in the world, despite its efforts to rid the country of cigarettes through prohibition.
The FDA is unnecessarily making your life more difficult.
A study found a "high rate of substitution" between vapes and cigarettes, suggesting that policies aimed at preventing underage use are undermining public health.
Removing high tariffs from foreign imports of baby formula would ease the supply shock of possible factory closures.
Legal restrictions on pseudoephedrine have not reduced meth use, but they have driven people with colds or allergies toward substitutes that seem to be completely ineffective.
The change, while welcome, is modest and won't get rid of patients' headaches as they try to fill their prescriptions.
The founder of MAPS talks about FDA approval for MDMA-assisted therapy and the "psychedelic renaissance" he has helped create.
The 1988 case highlighted the DEA's stubborn insistence that marijuana has no "accepted medical use."
Although the HHS-recommended change would benefit researchers and the cannabis industry, it would not resolve the conflict between state and federal marijuana laws.
Although it would leave federal prohibition essentially untouched, the change would facilitate medical research and dramatically reduce taxes on state-licensed suppliers.
The U.S. Court of Appeals for the D.C. Circuit takes issue with how the FDA evaluated Fontem's unflavored vaping products.
While schoolchildren go without needed medication, government agencies shirk responsibility by blaming manufacturers.
Painkiller reflects an indiscriminate anti-opioid bias that has caused needless suffering.
Plus: Court urged to stop Arkansas' social media age verification law from taking effect in September, legalizing medical marijuana linked to lower insurance premiums, and more...
On this one issue, the democratic socialist sounds a lot like a libertarian.
The FDA failed to consider whether premium cigars warranted a different regulatory approach than cigarettes.
Season 1, Episode 1 Podcasts
A combination of "absurdly high" federal tariffs and excessive FDA regulations created the conditions for a crisis.
No one could have considered this possibility, except perhaps the many food-processing facilities that immediately did exactly that.
A recent House committee investigation exposed political interference when it came to figuring out the origins of COVID. But why?
Plus: Does Tom Cruise really do all of his own stunts?
The FDA decision is only a mini step toward freeing the pill.
The new energy drink has about as much caffeine as a large Starbucks coffee.
As beef prices increase, biotech could provide a cheaper and tasty alternative.
Since the FDA began regulating vaping products as "tobacco" products, American ignorance about vaping's realtive risks has gotten worse.
A more flexible model of oversight avoids hyper-cautious top-down regulation and enables swifter access to the substantial benefits of safe A.I.
His licensing proposal would slow down A.I. innovation without really reducing A.I. risks.
A recent study finds that human challenge trials are largely safe.
Plus: No one is excited about a 2024 rematch between Biden and Trump, it's showtime for House Republicans' debt ceiling bill, and more...
Mifepristone will remain on the market for now with no changes to how it can be prescribed.
Officials who often get it wrong can’t be trusted to reliably decree what’s true.
The appeals court's unpublished order avoids some of the district court's errors, but still has some significant problems, especially with regard to standing.
It’s not the FDA’s job to tell doctors what to do.
Plus: The editors respond to a listener question concerning corporate personhood.
The divergent orders from judges in Washington state and Texas may bring the battle over mifepristone to the Supreme Court.
On Good Friday, two district courts issued decisions on the FDA's approval of the abortion drug mifepristone.
Litigation over abortion drugs turns disagreements about individual rights into a bureaucratic tussle.
And this lawsuit faces many of the same administrative law hurdles as does AHM v. FDA.
The life-saving drug stops opioid overdoses as they happen, restoring breathing and preventing death. Why did it take so long for the FDA to expand its use?
Thanks to onerous regulations, life-saving drugs are more expensive and harder to get.
ADF's Erin Hawley responds to my post on the jurisdictional problems in AHM v. FDA and I reply.
Do you care about free minds and free markets? Sign up to get the biggest stories from Reason in your inbox every afternoon.
This modal will close in 10